2026-05-20T03:47:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/228062025-05-07T10:33:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16970col_20.500.12105_16973col_20.500.12105_16980col_20.500.12105_16982col_20.500.12105_16990

00925njm 22002777a 4500 dc Chaparro, Maria author Barreiro-de Acosta, Manuel author Benitez, Jose Manuel author Cabriada, Jose Luis author Casanova, Maria Jose author Ceballos, Daniel author Esteve, Maria author Fernandez, Hipolito author Ginard Vicens, Daniel author Gomollon, Fernando author Lorente, Rufo author Nos, Pilar author Riestra, Sabino author Rivero, Montserrat author Robledo, Pilar author Rodriguez, Cristina author Sicilia, Beatriz author Torrella, Emilio author Garre, Ana author Garcia-Esquinas, Esther author Rodríguez-Artalejo, Fernando author Gisbert, Javier P author EpidemIBD study group of GETECCU author 2019-05 Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn's disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD. Chaparro M, Barreiro-De Acosta M, Benitez JM, Cabriada JL, Casanova MJ, Ceballos D, et al. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Ther Adv Gastroenterol. 2019 May;12:1-11. 10.1177/1756284819847034 1756-2848 1756-283X Therapeutic Advances in Gastroenterology http://hdl.handle.net/20.500.13003/9949 31205485 L627801194 2-s2.0-85066879289 https://hdl.handle.net/20.500.12105/22806 478873800001 Epidemiology Inflammatory bowel disease Crohn's disease Ulcerative colitis Incidence EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain